



2018 ONCOLOGY ANNUAL REPORT



PARK NICOLLET FRAUENSHUH CANCER CENTER
REGIONS HOSPITAL CANCER CARE CENTER
HEALTHPARTNERS CANCER CARE CENTER - RIVERSIDE
PARK NICOLLET CLINIC & SPECIALTY CENTER - BURNSVILLE
PARK NICOLLET CLINIC & SPECIALTY CENTER - MAPLE GROVE

PARK NICOLLET
FRAUENSHUH
CANCER CENTER

&

HEALTHPARTNERS
CANCER CARE
CENTERS



RANDY HURLEY, MD
Medical Director
HealthPartners and Regions Hospital
Cancer Care Centers
randy.w.hurley@healthpartners.com



MARK A. WILKOWSKE, MD
Medical Director
Park Nicollet Frauenshuh Cancer Center
mark.wilkowske@parknicollet.com



LAURA HOLASEK
Administrative System Director
Oncology Services
HealthPartners and Park Nicollet
laura.holasek@parknicollet.com

Expert, compassionate care that's close to home

HealthPartners Cancer Care Centers and Park Nicollet Frauenshuh Cancer Center believe in caring for the whole patient. We do that by providing the highest quality comprehensive care and focusing on timely appointments so patients and families can quickly get the answers they need. We're also committed to furthering cancer care through expanded research and access to extensive clinic trials right here in the metro area. Our physicians and care teams are inspired by our patients to offer the best possible care. Our 2018 annual report highlights that dedication to providing expert, compassionate care that's close to home.

When facing a potentially life-altering diagnosis such as cancer, patients and families need immediate answers to their questions. We stand by our 48-hour promise. This is our commitment to see a patient within 48 hours of a cancer diagnosis. To further support access, Richard Peterson, MD, Neuro Oncologist, will begin seeing patients with brain tumors at Park Nicollet.

Our ongoing commitment to research is reinforced by the recent announcement of the Oncology Research Center led by Dylan Zylla, MD, MS. This center combines our longstanding areas of research under one umbrella to better serve a larger number of patients. We are actively involved in a number of research trials and projects, including continuing research on the effectiveness of medical cannabis in easing patient discomfort. Our newly created center includes all Phase 1, 2 and 3 clinical trials. Phase 1 clinical trials, led by Arkadiusz Dudek, MD, offer patients access to emerging treatment options without traveling to faraway institutions. We're grateful to our foundations and donors for their support of our research efforts.

We continue to grow and build partnerships across the Twin Cities and Western Wisconsin. We would like to recognize Hutchinson Health as our newest partner. We continue our longstanding tradition of high quality, compassionate care and innovative treatment options to help support our patients and the communities we serve. Our high standards in caring and supporting the whole patient is demonstrated by our certification from the American College of Surgeons' Commission on Cancer and participation in the American Society of Clinical Oncology's Quality Oncology Practice Initiative.

If you have questions about this report or the exceptional care we strive to offer every patient, please contact us.



ASCO'S QOPI CERTIFICATION



Cancer care locations

MINNESOTA


1. HealthPartners Riverside Cancer Care Center
2. Lakeview Hospital Cancer Care
3. Park Nicollet Clinic & Specialty Center
Burnsville Infusion Center
4. Park Nicollet Clinic & Specialty Center
Maple Grove Infusion Center
5. Park Nicollet Frauenshuh Cancer Center
6. Regions Hospital Cancer Care Center
7. St. Francis Cancer Center

8. Hutchinson Health
NEW – Welcomed into our family of care in 2018

WISCONSIN

9. Amery Hospital and Clinic
Cancer Center of Western Wisconsin*
10. Hudson Hospital
Cancer Center of Western Wisconsin*
11. Osceola Medical Center
Cancer Center of Western Wisconsin*
12. St. Croix Regional Medical Center
Cancer Center of Western Wisconsin*
13. Western Wisconsin Health
Cancer Center of Western Wisconsin*
14. Westfields Hospital
Cancer Center of Western Wisconsin*

*HealthPartners provides physician services in partnership with Cancer Center of Western Wisconsin



MINNESOTA

WISCONSIN

Highlights of 2018

NEW ONCOLOGY RESEARCH CENTER WILL ALIGN, CENTRALIZE EFFORTS



Dylan Zylla, MD, MS – Has been named medical director of the newly created Oncology Research Center. The center will align and centralize the areas of oncology research from HealthPartners Cancer Care Centers and Frauenthuh Cancer Center to improve efficiencies and collaboration. This new role is in addition to his other leadership roles as a physician and researcher.

Dr. Zylla is a high energy, innovative and collaborative leader with a passion for symptom management research and quality improvement. He recently won the Association of Community Cancer Centers' innovation award for leading an 18-month project, Establishment of Personalized Pain Goals in Oncology Patients to Improve Care and Decrease Costs. He is also studying other ways to improve quality of life in patients with cancer through his ongoing projects evaluating medical cannabis, mu-opioid receptor expression, electronic patient-reported outcomes and hyperglycemia management during chemotherapy.

He will be teamed with Michele Lacy, RN, OCN, who will be assuming the role of administrative director along with her duties as the administrative director of Metro-Minnesota Community Oncology Research Consortium (MMCORC). Michele's excellent operational leadership skills and ability to build strong relationships will be a major asset. Together, they will be accountable for leading and supporting the work of the new Oncology Research Center.

NEW STAFF

One of the strengths of our program is talented, dedicated colleagues. In 2018, we welcomed several new members to our team.

Caroline Abenakyo, MA, NP-C
Sarah Benthein, RN
Janet Brock, RN
Xee Cha, RMA
Cynthia Crotty, RN
Jina Hagen
Allison Heald, RN
Lauren Hellstrom, RN
Julie Heyd, MS, BA, CTR

Carrie Hickey, RN
Lisa Huset, PA-S
Geleyna Jones
Malibu Korkalo, RN
Heather Leland, RN, BSN
Beverly Lubesmier
Lori McAree
Nora Nashawaty
Alexandra Nepsund, RN

Therese Otten, MA
Ashely Peetsch, RN
Rachel Recknagel, EMIC, RN
Cierre Sroda, PA-C
Somu Suppiah, MD
Lisa Tucker, CMA
Kimberly Woodman, RN, BSN



AWARDS AND ACHIEVEMENTS

Balkrishna Jahagirdar, MD – Recognized for his leadership to the Minnesota Society of Clinical Oncology (MSCO) with a lifetime achievement award. This award honored his lifelong commitment and dedication to improving the quality of life and care for oncology and hematology patients in Minnesota.

Randy Hurley, MD – Received the excellence in education award from Rein in Sarcoma, an organization dedicated to research, patient support and education. Dr. Hurley was honored for his ongoing passion and knowledge about sarcoma education.

Dawn McDougal Miller, MME, MT-BC – Accepted a lifetime achievement award from Music Therapy Association of Minnesota (MTAM), a group that strives to enhance quality music therapy services.

Anne Nelson, RN and Lori Christian, RN – Received the Good Catch for Patient Safety Award from the Minnesota Hospital Association.

Grateful Patient is a program at Regions Hospital that allows patients and family members to recognize and thank staff who made a difference in their lives. Several members of the oncology staff were recipients.

- Randy Hurley, MD
- Ciarra Sroda, AC-P
- Emina Mujcic, RN

Leadership in professional organizations

MINNESOTA SOCIETY OF CLINICAL ONCOLOGY

We continue to provide leadership and support to the Minnesota Society of Clinical Oncology. This group works to provide advocacy for patients with cancer and promote standards of excellence for high-quality cancer care.

Secretary/Treasurer:

Priya Kumar, MBBS, MS

Educational Program
Chair and Lifetime

Achievement Award:

Balkrishna Jahagirdar, MD

Member-at-Large:

Yan Ji, MD

Member-at-Large:

Melissa M. Sherman, MD

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

This group develops and conducts clinical trials, as well as researches methods to alleviate side effects of cancer and cancer treatments.

Principal Investigator, Board Member and Co-Chair, community oncology committee:

Dan Anderson, MD

Experimental therapeutics committee:

Balkrishna Jahagirdar, MD

Neuro-oncology committee:

Richard Peterson, MD

METRO MN ONCOLOGY NURSING SOCIETY

We're proud to have several colleagues in leadership roles in an organization dedicated to promoting their profession, colleagues and patients.

President or President-elect:

Adina Peck, ANP, GNP

Secretary:

Mary Ehresman, FNP, ADCN

Treasurer:

Cindy Jacobson, RN, ONC

Director-at-Large:

Nancy Anson, RN, ONC

Director-at-Large:

Mary Holland, BSN, OCN



NEW CREDENTIALS

Team members mastered additional skills and received oncology certified nursing credentialing.

Amy Feist, RN, OCN

Jenny Graves, RN, OCN

Patti Schmidt, RN, OCN

Amber Voss, RN, OCN

Community awareness and support

HealthPartners and Park Nicollet oncology programs are actively involved in programs to increase cancer screenings, community awareness and support for cancer patients.

A Breath of Hope Lung Foundation

This organization fights lung cancer by funding innovative research, raising awareness and supporting patients and families. We partnered with them at a number of events in 2018.

- **Minnesota Thought Leader's Meeting**
Joined this city-wide work group with the goal of increasing the number of Minnesotans screened for lung cancer.
- **Annual Walk/Run**
Sponsored this event, including staffing an information booth, in Minneapolis in August 2018.
- **Shining Bright Gala**
Engaged in this November event.
- **Lung Cancer Summit**
Participated in a one-day summit for those impacted by lung cancer. The goal is to provide education and resources to lighten the burden of cancer for patients and caregivers.

Open House at Park Nicollet Frauenshuh Cancer Center

Celebrated an expansion that includes additional clinic, treatment and integrative therapy space. The event was open to the public and included a cancer prevention and awareness fair, including information on radon testing and awareness, HPV, genetics and nutrition, as well as colon and breast cancer screening. This expansion was made possible through generous donors and Park Nicollet Foundation's Love and Legacy campaign.

Nutrition in Breast Cancer Prevention

Sponsored a discussion and cooking demonstration on preventing breast cancer. The event took place at Regions Hospital in October 2018.

Lung Cancer Support Group

Started in 2017, this monthly group provides an opportunity for patients with lung cancer to connect. There's a sense of empowerment and belonging when meeting others with a similar cancer diagnosis. The group meets at Regions Hospital. Call **651-254-2426** to learn more.

Neuro Oncology Summit: Thinking Differently About a Brighter Tomorrow

One of the highlights of this May 2018 summit was the Support on the Journey segment, which featured neuro oncology patient flow from the hospital to the clinic and beyond.

Rein in Sarcoma Party in the Park

This event celebrated sarcoma patients, survivors and their loved ones in July 2018. We were a sponsor.

Humor to Fight the Tumor

This September 2018 gala helped raise funds for brain tumor research. We were a gold sponsor.

Brain Tumor 5K Twin Cities Run & Walk

We sponsored this event at Lake Phalen in St. Paul to raise funds for brain tumor research in October 2018.

Other organizations and events we supported include Crohn's and Colitis Foundation, Cancer Legal Care, Irritable Bowel Disease Patient Education Conference and National Football League's Touch of Football.

Education and research

Critical to our mission of helping patients with cancer is our engagement in education and research. Teaching and education ensure that our clinicians and staff keep pace with new discoveries in the diagnosis of cancer and treatment. Research, through participation in clinical trials, gives our patients access to new therapies. We're also taking a leading role in research. We offer a variety of clinical trials at our facilities.

HealthPartners and Park Nicollet co-direct the Metro-Minnesota Community Oncology Research Consortium (mmcorc.org), an affiliation of 22 metro area hospitals. This consortium, sponsored by National Cancer Institute and area hospitals, allows patients in our community to access 100 cancer clinical trials. This program's administrative center is housed at Park Nicollet. HealthPartners physicians Dan Anderson, MD, and Rich Peterson, MD, are the program's principal investigator and assistant principal investigator.

In addition, HealthPartners and Park Nicollet Oncology Research Center sponsor a number of on-going clinical trials.



HEALTHPARTNERS PARK NICOLLET ONCOLOGY RESEARCH CENTER CLINICAL TRIALS

A Randomized Trial of Medical Cannabis in Patients with Advanced Cancers to Assess Impact on Opioid Use and Cancer-Related Symptoms: A Pilot and Feasibility Study

AML-03: Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML, and Oligoblastic AML

Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry

KRT-232-101: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed Ruxolitinib

ARRAY 382-201: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors

STM-03: Phase I Study of Procaspace Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

Array 818-103: A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

HCRN MEL16-261: Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody with High Dose IL-2 in Metastatic Melanoma

OMS-I103 (PISCES): A Multi-center Phase 2, Open-Label Trial of Intratumoral PIL-12 Plus Electroporation in Combination with IV Pembro in Patients with St III/IV Melanoma who are Progressing on either Pembro or Nivolumab Treatment

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

HCRN GU15-215: A Randomized Phase II Trial of Atezolizumab with or without Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer.

HCRN LUN15-233: Randomized Phase II Trial of single agent chemotherapy plus Nivolumab or single agent chemotherapy alone in patients with advanced squamous or non-squamous NSCLC with primary resistance to prior PD-1 or PD-L1 inhibitor

HCRN LUN15-299: Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma

MK3475 PN-544: A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects with Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN Who Have Failed Pembrolizumab Monotherapy or Who Are Actively Experiencing Stable Disease Following Completion of at Least 4 Cycles, but No More than 8 Cycles, of Pembrolizumab Monotherapy

MK3475-564: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

PROPEL 16-214-05: A Phase 1B, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 In Combination with Anti-PD-1 (pembrolizumab) or Anti-PD-L1 (atezolizumab) In Patients With, Locally Advanced or Metastatic Solid Tumors

POLARIS A5481082: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

TTC-352-101: Study of TTC-352 in Patients with Metastatic Breast Cancer Progressing on Endocrine Therapy

SELECT PUBLICATIONS

Tan WW, Hillman DW, Salim M, Northfelt DW, **Anderson DM**, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydro-chloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. *Ann Oncol*. 2018 Oct 1;29(10):2150.

Palmieri F, Perez EA, Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, **Anderson DM**, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA. *Blood*. 2018 Jan 11;131(2):182-190.

Bhattacharyya S, Feferman L, Terai K, **Dudek AZ**, Tobacman JK. Decline in arylsulfatase B leads to increased invasiveness of melanoma cells. *Oncotarget*. 2017 Jan 17;8(3):4169-80.

Xie Z, Chen WS, Yin Y, Chan EC, Terai K, Long LM, Myers TG, **Dudek AZ**, Druuey KM. Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease). *J Leukocyte Biol*. 2018 Apr;103(4):749-59.

Schmidt TM, Liu LI, Abraham IE, Uy AB, **Dudek AZ**. Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. *Anticancer Res*. 2018 Jul;38(7):4027-4034.

D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, **Jahagirdar BN**, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. *Lancet Oncol*. 2018 Mar;19(3):416-26.

Denzen EM, Preussler JM, Murphy EA, Baker KS, Burns LJ, Foster J, Idossa L, Moore HK, Payton TJ, Haven D, **Jahagirdar B**, Kamani N, Rizzo JD, Salazar L, Schatz BA, Syrjala KL, Wingard JR, Majhail NS. Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2018 Oct 10.

Jansson-Knodell CL, Foster NR, Sargent DJ, Limburg PJ, Thibodeau SN, Smyrk TC, Sinicrope FA, **Jahagirdar BN**, Goldberg RM, Alberts SR. Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). *J Gastroenterol Oncol*. 2017 Feb;8(1):1-11.

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, **Jahagirdar B**, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtress B. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group. *J Clin Oncol*. 2017 Feb 10;35(5):490-7.

Phipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, **Jahagirdar BN**, Limburg PJ, Newcomb PA, Shields A, Sinicrope FA, Sargent DJ, Alberts SR. Physical activity and outcomes in patients with stage III colon cancer: a correlative analysis of Phase III Trial NCCTG N0147 (Alliance). *Cancer Epidemiol Biomarkers Prev*. 2018 Jun;27(6):696-703.

Piotrowska Z, Fintelmann FJ, Sequist LV, **Jahagirdar B**. Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma. *J Thorac Oncol*. 2018 Oct;13(10):e204-e206.

Johnson KJ, Minchew LA, Richter SA, Craft CE, **Lerner RE**. Providing breast cancer survivorship: lessons learned from a pilot project implementation. *Cancer Nurs*. 2017 Sep-Oct;40(5):E51-e61.

Pawloski PA, Kehn HL, **Anderson DM**. The financial toll of cancer therapy: developing ways to help the patient. *Minn Physician*. 2017 Aug;31(5):30-1.

Pawloski PA, Thomas AJ, Kane SM, Vazquez-Benitez G, **Shapiro GR**, Lyman GH. Predicting neutropenia risk in patients with cancer using electronic data. *J Am Med Inform Assoc*. 2017 Apr 1;24(e1):e129-35.

Buist DSM, Field TS, Banegas MP, Clancy HA, Doria-Rose VP, Epstein MM, Greenlee RT, McDonald S, Nichols HB, **Pawloski PA**, Kushi LH. Training in the conduct of population-based multi-site and multi-disciplinary studies: the Cancer Research Network's Scholars Program. *J Cancer Educ*. 2017 Jun;32(2):283-92.

Feigelson HS, McMullen CK, Madrid S, Sterrett AT, Powers JD, Blum-Barnett E, **Pawloski PA**, Ziegenfuss JY, Quinn VP, Arterburn DE, Corley DA. Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. *J Cancer Surviv*. 2017 Jun;11(3):393-400.

Touma W, Hoostal S, **Peterson RA**, Wiernik A, SantaCruz KS, Lou E. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. *J Clin Neurosci*. 2017 Jul;41:75-7.

Hussein HM, Dornfeld BJ, **Schneider DJ**. Nivolumab-induced posterior reversible encephalopathy syndrome. *Neurol Clin Pract*. 2017 Oct;7(5):455-6.

Shapiro GR. Introduction: decision making with older cancer patients. *Cancer J*. 2017 Jul-Aug;23(4):199-200.

Zylla DM, Larson AR, Chuy G, Illig LC, Peck AL, Van Peurse SA, Fulbright JW, **Pawloski PA**, Richter SA, Mettner J. Establishment of personalized pain goals in oncology patients to improve care and decrease costs. *J Oncol Pract*. 2017 Mar;13(3):e266-72.

Zylla DM, Steele GL, Gupta P. A systematic review of the impact of pain on overall survival in patients with cancer. *Support Care Cancer*. 2017 May;25(5):1687-98.

Zylla DM, Steele GL, **Shapiro AC**, Richter SA, Gupta P. Impact of opioid use on health care utilization and survival in patients with newly diagnosed stage IV malignancies. *Support Care Cancer*. 2018 Jul;26(7):2259-66.

Zylla, D., et al. Oncology clinicians and the Minnesota Medical Cannabis Program: a survey on medical cannabis practice patterns, barriers to enrollment, and educational needs. *Cannabis and Cannabinoid Research*. 2018 (Submitted).

Zylla, D., et al. Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. *Journal of Diabetes and Its Complications*. 2018 (Submitted).

Anderson, S, **Zylla, D.**, et al. Impact of medical cannabis on patient-reported symptoms for cancer patients enrolled in Minnesota's Medical Cannabis Program. *J Oncol Pract*. 2018 (Submitted).

Steele, G, Arneson, T, and **Zylla, D.** A comprehensive review of cannabis in patients with cancer: availability in the United States, general efficacy, and safety. *Current Oncology Reports*. 2018 (Submitted).



Palliative care: relief from the symptoms of a serious illness

Palliative care is specialized medical care that focuses on providing relief from the symptoms and stress of a serious illness, including cancer treatment. It's appropriate at any age and at any stage in serious illness. The goal is to improve the quality of life for the patient and the family.

HealthPartners and Park Nicollet incorporate palliative care specialists and resources into our daily practice, particularly for patients experiencing distressing symptoms or emotions from treatment. Medical studies support the benefits of reduced hospital readmissions, better quality of life, improved symptom control and heightened satisfaction amongst families.



Oncology symposiums provide continuing education

In collaboration with the staff at the Cancer Center of Western Wisconsin, Park Nicollet Frauenshuh Cancer Center and HealthPartners Cancer Care Centers provide oncology education symposiums for health care providers twice yearly.

The spring 2018 symposium on colorectal cancer included these presentations.

- Introduction to Colon Cancer by **Karen Rabenau, MD**
- Surgical Aspects of Colon Cancer by **Ryan Carlson, MD**
- Ostomy Care by **Jan Chevrette, FNP-C, CWO-CN, CFCN**
- Inherited Colon Cancer by **Katherine Fuhrmann, MS, Certified Genetics Counselor**
- Adjuvant Therapy of Colon Cancer by **Melissa Sherman, MD**
- Treatment of Metastatic Colon Cancer by **Balkrishna Jahagirdar, MD**

The fall 2018 symposium on caring for lymphoma patients included these presentations.

- Pathologic Classifications & Staging of Malignant Lymphoma by **Randy Hurley, MD**
- Hodgkin's Lymphoma by **Steve McCormack, MD**
- Low Grade Lymphoma by **Craig Mescher, MD**
- Intermediate and High Grade Lymphoma by **Yan Ji, MD**
- Review of Primary CNS Lymphoma by **Richard Peterson, MD**
- CAR T-Cell Therapy, a Primer for RNs by **Kurt Demel, MD**

Improving care for all patients with cancer

Our staff participates in a number of conferences and training seminars each year to help improve the care of patients with cancer.

HealthPartners Nursing Symposium, April 21, 2018

- Understanding Management of Metastatic Colorectal Cancer by **Balkrishna Jahagirdar, MD**

Park Nicollet New and Old Drugs: Best Choices, May 3, 2018

- Anemia Treatment 2018 by **Bryan Trottier, MD**

Park Nicollet Webex, May 30, 2018

- Pearls and Pitfalls: Benign Hematology by **Bryan Trottier, MD**

International Symposium on Malignant Mesothelioma, June 8, 2018, Minneapolis

- Novel Strategies for Treatment of Mesothelioma after Failure of Front Line Therapy by **Arkadiusz Dudek, MD, PhD**

HealthPartners Primary Care Pathway Conference, Sept. 21, 2018

- Round and Round: Common Challenges in Hematology by **Bryan Trottier, MD**

University of Minnesota Fellows' Core Curriculum, Sept. 24, 2018

- Adjuvant Treatment of Colorectal Cancers by **Balkrishna Jahagirdar, MD**

University of Minnesota Medical School, Fall, 2018

- How to Survive and Thrive in a Career in Medicine by **Jeffry Jaffe, MD**
- Internal Medicine Board Review in Oncology and Hematology by **Balkrishna Jahagirdar, MD**

Park Nicollet Lunch and Learn, Oct. 11, 2018

- Cannabis for Curious Clinicians – Pearls from a Patient's Perspective by **Dylan Zylla, MD**

Society for Immunotherapy of Cancer, Oct. 27, 2018, Minneapolis

- Basic Principles of Cancer Immunotherapy by **Arkadiusz Dudek, MD, PhD**
- Advances in Immunotherapy of Head and Neck Cancers by **Balkrishna Jahagirdar, MD**



TRAINING THE NEXT GENERATION OF ONCOLOGISTS

One of the core missions of our organization is to train the next generation of physicians and scientists to be leaders in the field of oncology. Regions Hospital is proud to host clinical training sites for the University of Minnesota Hematology and Oncology Fellowship Program. For more than 25 years, this training has included direct supervision of patient care, didactic lectures and informal teaching sessions. Each year, more than 50 hours of didactic lectures are provided to University of Minnesota medical students, internal medicine residents, hematology-oncology fellows, primary care and emergency room physicians, oncology nurses and pharmacists.

Screening and prevention

BE PINK AND BREAST CANCER AWARENESS

We continued our Be Pink campaign to encourage women in the Twin Cities to be aware, proactive and empowered with their breast health. This includes promoting screenings and early breast cancer detection. Our mobile mammography unit, Mammo-a-go-go, has increased use during the campaign.

HealthPartners, Regions Hospital and Park Nicollet Jane Brattain Breast Center participated again this year in the Susan G. Komen Race for the Cure on Mother's Day 2018. Using our Mammo-a-go-go as a backdrop for our booth space, we had notable event engagement, including people rushing over for our annual charm giveaway.

To kick off breast cancer awareness month in October, we presented Country for a Cause and the Be Pink fundraising breakfast in partnership with the Park Nicollet Foundation. These events benefit the Jane Brattain Breast Center community outreach fund providing mammograms to women in need.

COLORECTAL CANCER SCREENING

As part of Colorectal Cancer Screening Awareness month, a social media campaign and monitor screens in our clinics reminded people to schedule a colorectal screening. To reach even more patients throughout the year, we mailed FIT tests to those who hadn't been screened in our primary care clinics. FIT tests are an in-home stool sample kit that can be used as a preliminary screening for those who meet certain qualifications.

In September, we sponsored and participated in Get Your Rear in Gear: Tour de Tush race for colon cancer in Minneapolis. Approximately 1,000 participants stopped by our event tent for giveaways and information, including educational materials on FIT testing.

We continued our partnership with Sage, Minnesota's cancer screening program for low income residents, to screen about 175 patients in 2018.

LUNG CANCER SCREENING

HealthPartners launched a lung cancer screening program in 2017 to identify cancer at an earlier stage to save lives and decrease the cost of lung cancer treatment. Once the patient meets eligibility requirements, the program begins with a shared decision making and counseling session with the patient's primary care provider. This is followed by a low-dose CT scan. The program also requires results tracking, follow-up activity and submittal to the American College of Radiology (ACR) registry. Studies have shown that this form of secondary prevention can save lives and potentially reduce health care costs.

COMMUNITY WELL-BEING INITIATIVES

According to the American Cancer Society, certain cancer deaths can be prevented by living healthier lifestyles and "making healthy choices like not smoking, staying at a healthy weight, eating right, keeping active and getting recommended screening tests." HealthPartners promotes health and well-being in our communities through a variety of projects and initiatives designed to increase activity, encourage better food and beverage choices and reduce the number of people who use tobacco. With more than 55 primary care clinics across our system, these efforts reach thousands of patients and members each year.

SKIN CANCER SCREENING

Our combined oncology program, in conjunction with our dermatology departments, hosted a free skin cancer screening event for the community May 5, 2018. There were 158 participants, a 27 percent increase over 2017. Follow-up was recommended for nearly 37 percent of participants.

35% MALE

65% FEMALE

58 AVERAGE AGE

18% FAMILY OR PERSONAL HISTORY OF SKIN CANCER

45% TANNING BED USAGE

ACCOUNTABILITY MEASURES

These accountability measures indicate the portion of breast and colorectal cancer patients treated according to recognized standards of care by diagnosis year. The results are reported to the National Cancer Data Base (NCDB), a joint program of American College of Surgeons (ACoS) and American Cancer Society. NCDB is a nationwide oncology outcomes database for more than 1,500 commission-accredited cancer programs.

NCDB Select Breast and Colorectal Measures

		ESTIMATED PERFORMANCE RATES			NATIONAL BENCHMARK*
		2014	2015	2016	
BREAST CANCER					
Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast-conserving surgery for breast cancer.	HEALTHPARTNERS	95.5%	93.5%	96.8%	90%
	PARK NICOLLET	98.5%	98.5%	96.8%	
Combination chemotherapy is considered or administered within four months (120 days) of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ER and PR negative breast cancer.	HEALTHPARTNERS	100%	100%	100%	90%**
	PARK NICOLLET	100%	94.1%	85.7%	
Tamoxifen or third generation aromatase inhibitor is considered or administered within one year (365 days) of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ER and/or PR positive breast cancer.	HEALTHPARTNERS	97.6%	96%	98.1%	90%
	PARK NICOLLET	97.3%	96.6%	100%	
COLON CANCER					
Adjuvant chemotherapy is considered or administered within four months (120 days) of diagnosis for patients under the age of 80 with AJCC T1c Stage III (lymph node positive) colon cancer.	HEALTHPARTNERS	100%	83.3%	100%	90%**
	PARK NICOLLET	100%	100%	100%	
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.	HEALTHPARTNERS	95.7%	90.6%	98.2%	85%
	PARK NICOLLET	94%	89.1%	92.27%	

*Commission-approved programs **Noted as 2013 benchmark from NCDB

Oncology registry

MOST COMMON CANCER SITES


The four most common cancers for HealthPartners and Park Nicollet patients in 2017 (excluding skin cancers) were breast, prostate, lung and colorectal. These four sites account for 44 percent and 52 percent of all cases.

In Minnesota, the most common cancers listed in order of occurrence as published in the American Cancer Society's "Cancer Facts and Figures 2017," are breast, prostate, lung and colorectal. Table 2 compares by site and percent HealthPartners and Park Nicollet case totals with the estimated number of cancer cases in Minnesota and the U.S.

TABLE 1:
2017 Four Most Common Sites by AJCC Stage at HealthPartners and Park Nicollet


FEMALE BREAST CANCER

TOTAL CASES: 938




LUNG CANCER

TOTAL CASES: 441 (MALE 212, FEMALE 229)



PROSTATE CANCER

TOTAL CASES: 679



COLORECTAL CANCER

TOTAL CASES: 256 (MALE 144, FEMALE 112)




TABLE 2:
2017 Four Most Common Cancer Sites

Table 2 compares, by site and percentage, HealthPartners and Park Nicollet case totals with estimated number of cancer cases in Minnesota and the U.S.

BREAST CANCER

15%

Cancer cases at
HealthPartners

23%

Cancer cases at
Park Nicollet

15% of cancer patients in the United States
have breast cancer. 14% in Minnesota

PROSTATE CANCER

12%

Cancer cases at
HealthPartners

16%

Cancer cases at
Park Nicollet

10% of cancer patients in the United States
have prostate cancer. 9% in Minnesota

LUNG CANCER

11%

Cancer cases at
HealthPartners

8%

Cancer cases at
Park Nicollet

13% of cancer patients in the United States
have lung cancer. 12% in Minnesota

COLORECTAL CANCER

6%

Cancer cases at
HealthPartners

5%

Cancer cases at
Park Nicollet

8% of cancer patients in the United States
have colorectal cancer. 7% in Minnesota

TABLE 3:
2017 Tumor Registry

HealthPartners and Park Nicollet tumor registries contain a comprehensive profile of all newly diagnosed cancer using standards set by the American College of Surgeons.

	HEALTH PARTNERS		PARK NICOLLET	
	2016	2017	2016	2017
ANALYTIC CASES*	1,868	2,049	2,503	2,690
NON-ANALYTIC CASES**	90	292	29	0
PERCENTAGE OF CASES PRESENTED AT TUMOR CONFERENCES (GENERAL, GYN, BREAST, LUNG)	36.9% (572)	36.4% (582)	24% (608)	24% (645)

*Analytic: cases diagnosed and/or having initial therapy at HealthPartners or Park Nicollet

**Non-analytic: cases having all initial therapy elsewhere, seen at HealthPartners or Park Nicollet for further care and treatment

TABLE 4:
2017 Cancer Cases Diagnoses by Tumor Site and Gender

CANCER TYPE	HEALTHPARTNERS			PARK NICOLLET		
	TOTAL	MALE	FEMALE	TOTAL	MALE	FEMALE
ANUS	8	4	4	9	1	8
BLADDER	61	41	20	103	69	34
BRAIN AND ONS	131	57	74	52	32	20
BREAST	310	2	308	628	2	626
COLORECTAL	116	74	42	140	70	70
ENDOCRINE	59	23	36	49	14	35
ESOPHAGUS	22	20	2	27	26	1
HEAD & NECK	58	42	16	50	37	13
KIDNEY / RENAL	49	35	14	63	45	18
LEUKEMIA	40	25	15	79	43	36
LUNG	225	116	109	216	96	120
LYMPHOMA	81	38	43	110	57	53
MULTIPLE MYELOMA	20	11	9	26	20	6
OTHER GI	73	43	30	61	35	26
OTHER / ILL-DEFINED	70	36	34	54	31	23
OVARY	29	0	29	31	0	31
PANCREAS	47	26	21	54	25	29
PROSTATE	243	243	0	436	436	0
SKIN	240	146	94	346	209	137
TESTIS	11	11	0	16	16	0
UNKNOWN PRIMARY	14	6	8	20	11	9
UTERUS	117	0	117	115	0	115
VULVA	25	0	25	5	0	5
TOTAL	2,049	999	1,050	2,690	1,275	1,415

Quality performance

We continuously measure clinician and system performance to improve quality and to assist in quickly incorporating new medical knowledge into our care.

PATIENT REPORTED OUTCOME SURVEY (PROMS)

This project in oncology aims to collect outcome metrics on symptoms from patients at clinic visits, before and after chemotherapy. The project utilizes a validated symptom survey tool which is sent to patients through automated emails and electronic collection methods at the point of care. Oncology patients have the opportunity to complete the survey at home. If patients are not able to complete the survey prior to an appointment, they will be asked to complete the PROMS via iPad. The PROMS system sends data to EPIC upon user completion of the survey. This allows the care team to see and monitor symptoms in real time.

BEACON ORAL CHEMOTHERAPY INITIATIVE

This initiative allows oncologists to order oral chemotherapy in the same way infused chemotherapy is ordered. The goal is to provide consistency in the ordering and documentation process. The oral chemotherapy initiative went live in November 2018.

CARING FOR PATIENTS WITH DIABETES AND CANCER

The goal is to improve clinical outcomes for patients with diabetes and cancer receiving chemotherapy with steroid medications. A pilot program is underway to improve risk assessment and detection of patients with diabetes as well as understand the scope of problems and areas of focus. The results will be used to create a diabetes intervention initiative in our cancer centers.

IMPROVE WELL PROJECT

This quality improvement work focused on reducing delays in receiving chemotherapy at Regions Hospital Cancer Care Center. The goal was to decrease average infusion wait times from Beacon chemotherapy plan approval to starting treatment.

QUALITY ACADEMY AKI WITH CISPLATIN

Cisplatin-associated nephrotoxicity is unpredictable but associated with significant morbidity and mortality. It has the potential to diminish quality of life and compromise treatment. The team's aim is to minimize Cisplatin-associated nephrotoxicity by implementing renal-protective measures and a risk stratification model into Beacon protocols.



Dedicated to providing excellent care

On average, **95.6** percent of patients would recommend our providers. That exceeds the national average of 84.3 percent, according to the National Research Council. Other ratings by our patients include:

- Would recommend: **95.5%**
- Rate your provider: **90.4%**
- Provider listened: **97.0%**
- Provider knew my medical history: **93.4%**
- Provider showed respect for what the patient said: **97.5%**

Give hope. Give possibility.

In 2017, through Regions Hospital Foundation and Park Nicollet Foundation, 1,046 donors gave more than \$500,000 to support meaningful care for those affected by cancer at Regions Cancer Center and Park Nicollet Frauenshuh Cancer Center.

Park Nicollet Foundation

Donors make it happen

You ensure the sustainability of Frauenshuh Cancer Center programs, including:

- Clinical cancer research
- Music, massage and other therapies
- Non-moving patient care model
- Patient special needs
- Patient support groups and education
- Survivorship program

Be a part of our mission in action

Contact Park Nicollet Foundation at **952-993-5023** or **foundation@parknicollet.com**.



Regions Hospital Foundation

Donors bring hope to patients with cancer

Your generous gifts to Regions Hospital Cancer Care Center support:

- Basic needs assistance
- Care navigation assistance
- Classes and support groups
- Clinical cancer research
- Music and massage therapy

Find out how you can make a difference

Contact Regions Hospital Foundation at **651-254-2376** or **rhf@healthpartners.com**.



"My wife and I were both treated really well by Frauenshuh Cancer Center. If by donating, I am able to make sure other patients have the best care, then it serves my wife's memory, and it means a lot to me."

– GARY, CAREGIVER, CANCER SURVIVOR, DONOR, VOLUNTEER



"We want to help others focus on living while they're undergoing treatment."

– MEGAN GANGL

Megan Gangl and the Mahtomedi High School Track team raise money each year to support fun family activities for Regions Hospital patients receiving cancer treatment.

Cancer committee members 2018

Our cancer committees meet quarterly to review all aspects of our program. This includes information related to cancer conferences, community outreach, research and quality improvement, as well as all the teams involved in cancer care.

HEALTHPARTNERS

Sue Braaten, RHIT, CTR
Oncology Registry

Diana Christensen Johnston, RN, OCN
Nurse Manager, Cancer Center

Linda Christensen-Rengel, NP
Breast Health Center

Christine Colbach, MD
Pathology

Kevin Collis, RN, OCN
Nurse Navigator

Kim Duffy, RD
Food and Nutritional Services

Holly Guida, RN-BSN, MBA
Oncology Operations Specialist

Laura Holasek
Director, Cancer Center

Randy Hurley, MD
Medical Oncology

Cindy Johnston
Genetic Counselor

Karen Lin, CTR
Cancer Registry

Rory Malloy
Quality Management

Pam Mason
American Cancer Society

Todd Morris, MD
General Surgery,
Surgical Oncology

Gretchen Niemioja, MD
Rehabilitation Services

Jennifer Pluff, CTR
Oncology Registry

Trisha Prescott, MD
Radiology

Amanda Richards, RN, OCN, BSN
Research

James Risser, MD
Internal Medicine, Palliative Care

Rob Ruff
Pastoral Care

Charles Shideman, MD
Radiation, Oncology

James Schlaefer, MD
General Surgery,
Surgical Oncology
(Cancer Liaison Fellow,
American College of Surgeons)

Caitlyn Squire, LICSW, OSW-C
Social Services

Bonnie Sweeney, RN
Nursing

Beth Werner, RN, MS, CHPN, CHPCA
HealthPartners Hospice
and Palliative Care

PARK NICOLLET

Christopher Chow, MD
Colon and Rectal Surgery

Justin Eklund
Clinical Research

Britt Erickson, MD
Gynecology Oncology

Jim Ferguson
Chaplain

Kelly Furda, MD
Radiologist

Nancy Gelle, BSN, RN
Palliative Care,
Home Care, Hospice

Howard Haines, MN
Emergency Medicine

Michael Haley, MD
Radiation Oncology

Kristin Hanrahan
Quality Improvement

Megan Hanson, MS, CGC
Genetics

Keith Heaton, MD
General Surgery,
Surgical Oncology
(Cancer Liaison Fellow,
American College of Surgeons)

Laura Holasek
Director, Cancer Center

Anne Hopkins, RN, OCN
Oncology Program Manager

Christian Loger
Jane Brattain Breast Center

Pamela Mason
American Cancer Society

Matt McCoy, MD
Pathology

Vicki Norton, BSN, OCN, RN
Nursing

Carol Ann Petersen, LICSW, MAHS
Patient Support and Education

Jocelyn Rieder, MD
Urology

Emily Schoh, RN
Nursing

Bryan Schuler, PharmD, BCOP
Pharmacy

Jane Siekkinen, BS, CTR
Oncology Registry

Paul Spilde, PT
Rehabilitation Services

Eric Weinberg, MD
Diagnostic Radiology

Mark Wilkowske, MD
Medical Oncology

Oncology provider team

Caroline Abenakyo, MA, NP-F

Daniel Anderson, MD

Peter Argenta, MD

Kacy Berquist, MSN, APRN, NP-C

Linda Carson, MD

Joel Carter, MD

Cathleen Chen, MD

Janel Cox, MD

Kurt Demel, MD

Arkadiusz Dudek, MD, PhD

Mary Ehresman, FNP, ADCN

Britt Erickson, MD

Brad Farrell, PharmD

Lori Fewer, CFNP

Chitra Ganesan, MBBS

Monique Giordana, PharmD

Michael Haley, DO

Robert Haselow, MD

Keith Heaton, MD

Jason Hoiness, PharmD

Peter Hurley, MD

Randy Hurley, MD

Lisa Huset, PA-C

Gretchen Ibele, MD

Lisa Illig, MD

Jeffrry Jaffe, MD

Balkrishna Jahagirdar, MD

Kathryn Jelle, PA-C

Yan Ji, MD

Carol Jirik, RN

Stephanie Kroon, PA-C

Kendra Kubiak, MD

Priya Kumar, MD

Brenda Larson, MD

Rachel Lerner, MD

Ayse Malcolm, MD

Sarah Manuels, MPAS, PA-C, MPH

Steven McCormack, MD

Mark Menge, MD

Craig Mescher, MD

Kathryn Moore, MD

Sally Mullany, MD

Gretchen Niemioja, MD

Jason Oakes, PA-C

Adina Peck, ANP, GNP

Richard Peterson, MD

Karen Rabenau, MD

Brian Rank, MD

Anne Reiber, ANP, GNP

Daniel Schneider, MD

Melissa Sherman, MD

Gary Shapiro, MD

Charles Shideman, MD

Mary Spengler, RNC, ANP

Amy Spomer, MD

Cierra Sroda, PA-C

Somu Suppiah, MD

Deanna Teoh, MD

Jane Thompson, PharmD

Kandice Tolic, NP-WH

Bryan Trottier, MD

Punit Wadhwa, MBBS

Mark Wilkowske, MD

Dylan Zylla, MD, MS

HealthPartners Institute

Advancing health and health care

HealthPartners Institute is a 501c3 non-profit organization with researchers dedicated to conducting high-quality, public-domain health research. The institute is an affiliate member of Cancer Research Network (CRN) and a participant in the National Cancer Institute-funded CRN IV program. HealthPartners research includes projects and initiatives of Park Nicollet. Pamala Pawloski, PharmD, is the site primary investigator and a CRN scholar, a role that allows her to be a mentor to new investigators. Visit healthpartners.com/institute to learn more.

To make an appointment, call:

Park Nicollet Frauenshuh Cancer Center
952-993-3248

Regions Hospital Cancer Care Center
651-254-3572

HealthPartners Cancer Care Center – Riverside
612-341-4800

Park Nicollet Clinic & Specialty Center – Burnsville
952-993-3248

Park Nicollet Clinic & Specialty Center – Maple Grove
952-993-3248

For more information or to make a referral, contact Laura Holasek at laura.holasek@parknicollet.com or **651-254-4656**